ACC.24 - Can treatment with the selective aldose reductase inhibitor AT-001 prevent deterioration of exercise capacity and the onset of HF in patients with diabetic cardiomyopathy? James Januzzi shares the results of ARISE-HF.
Effect of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
Restart
Resume
Transcript
Effects of aldose reductase inhibitor on exercise capacity in diabetic cardiomyopathy
closeShare this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Overview
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
James Januzzi is the Adolph Hutter Professor of Medicine at Harvard Medical School, Boston, MA, US. He also is the Director of Heart Failure Clinical Trials at the Baim Institute for Clinical Research, a staff cardiologist at the Massachusetts General Hospital, and a Trustee of the American College of Cardiology.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 23 April 2024
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
ACC.24 - Can treatment with the selective aldose reductase inhibitor AT-001 prevent deterioration of exercise capacity and the onset of HF in patients with diabetic cardiomyopathy? James Januzzi shares the results of ARISE-HF.
Educational information
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Faculty
James Januzzi is the Adolph Hutter Professor of Medicine at Harvard Medical School, Boston, MA, US. He also is the Director of Heart Failure Clinical Trials at the Baim Institute for Clinical Research, a staff cardiologist at the Massachusetts General Hospital, and a Trustee of the American College of Cardiology.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 23 April 2024
Presenters
Facebook Comments